Celgene, Hayman Capital Management cancer news

The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office instituted an inter partes review (IPR) petition from Kyle Bass’ Coalition for Affordable Drugs challenging a patent covering Revlimid lenalidomide from Celgene.

U.S. Patent No. 6,045,501 covers methods for preventing fetal exposure to teratogenic drugs. It was issued in 2000 and is set to expire in 2018. It is one of 27 Orange Book-listed patents covering Revlimid; the last expires in 2028. ...